marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-06-2024
Ionis Pharmaceuticals Balance Sheet 2011-2024 | IONS
Annual Balance Sheet Ionis Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
850 M | -90.3 M | -850 M | 141 M | 104 M | 368 M | 478 M | 432 M | 280 M | 243 M | 1.31 M | 31.8 M | 153 M |
Long Term Debt |
1.24 B | 179 M | 19.4 M | 539 M | 786 M | 633 M | 606 M | 516 M | 400 M | 383 M | 157 M | 151 M | 215 M |
Long Term Debt Current |
8.09 M | 7.22 M | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 1.28 B | 1.2 B | 679 M | 679 M | 606 M | 583 M | 371 M | 289 M | 237 M |
Total Current Liabilities |
448 M | 312 M | 241 M | 583 M | 273 M | 280 M | 225 M | 134 M | 149 M | 115 M | 97.8 M | 74.3 M | 76.1 M |
Total Liabilities |
2.6 B | 1.96 B | 1.84 B | 1.55 B | 1.55 B | 1.48 B | 903 M | 813 M | 755 M | 698 M | 469 M | 363 M | 313 M |
Deferred Revenue |
151 M | 90.6 M | 97.7 M | 108 M | 118 M | 160 M | 106 M | 51.3 M | 67.3 M | 51.7 M | 48.1 M | 35.9 M | 36.6 M |
Retained Earnings |
-1.8 B | -1.43 B | -1.16 B | -1.25 B | -708 M | -967 M | -1.19 B | -1.18 B | -1.09 B | -1.01 B | -968 M | -907 M | -841 M |
Total Assets |
2.99 B | 2.53 B | 2.61 B | 2.39 B | 3.23 B | 2.67 B | 1.32 B | 912 M | 956 M | 956 M | 847 M | 546 M | 485 M |
Cash and Cash Equivalents |
399 M | 276 M | 869 M | 398 M | 683 M | 279 M | 130 M | 84.7 M | 129 M | 143 M | 160 M | 124 M | 65.5 M |
Book Value |
387 M | 573 M | 772 M | 843 M | 1.68 B | 1.19 B | 419 M | 99.6 M | 201 M | 258 M | 378 M | 183 M | 171 M |
Total Shareholders Equity |
387 M | 573 M | 772 M | 743 M | 1.47 B | 1.05 B | 331 M | 99.6 M | 201 M | 258 M | 378 M | 183 M | 171 M |
All numbers in USD currency
Quarterly Balance Sheet Ionis Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
168 M | 166 M | 169 M | 171 M | 173 M | 175 M | 177 M | 179 M | - | - | - | - | - | - | - | 539 M | - | - | - | 786 M | 596 M | 587 M | 577 M | 568 M | 559 M | 568 M | 568 M | 533 M | 533 M | 533 M | 533 M | 501 M | 501 M | 501 M | 501 M | - | - | - | - | - | 155 M | 154 M | 152 M | 150 M | 149 M | 150 M | 150 M | 144 M | 144 M | 144 M | 144 M | 146 M | 4.72 M | 5.46 M | 4.94 M |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.42 B | 2.43 B | 2.47 B | 2.6 B | 2.62 B | 2.54 B | 2.4 B | 1.96 B | 1.83 B | 1.83 B | 1.81 B | 1.84 B | 1.88 B | 1.91 B | 1.57 B | 1.65 B | 1.65 B | 1.65 B | 1.65 B | 1.55 B | 1.55 B | 1.55 B | 1.55 B | 1.48 B | 1.48 B | 1.48 B | 1.48 B | 957 M | 957 M | 957 M | 957 M | 813 M | 813 M | 813 M | 813 M | 747 M | 747 M | 747 M | 747 M | 698 M | 698 M | 698 M | 698 M | 469 M | 469 M | 469 M | 469 M | 363 M | 363 M | 363 M | 363 M | 313 M | 313 M | 313 M | 313 M |
Deferred Revenue |
76 M | 94.1 M | 130 M | 151 M | 205 M | 96.3 M | 92.3 M | 90.6 M | 99.5 M | 93.4 M | 91.4 M | 97.7 M | 97.9 M | 102 M | 107 M | 108 M | 108 M | 108 M | 108 M | 118 M | 118 M | 118 M | 118 M | 160 M | 160 M | 160 M | 160 M | 106 M | 105 M | 111 M | 108 M | 51.3 M | 51.3 M | 51.3 M | 51.3 M | 67.3 M | 67.3 M | 67.3 M | 67.3 M | 51.7 M | 51.7 M | 51.7 M | 51.7 M | 48.1 M | 48.1 M | 48.1 M | 48.1 M | 35.9 M | 35.9 M | 35.9 M | 35.9 M | 36.6 M | 36.6 M | 36.6 M | 36.6 M |
Retained Earnings |
-2.15 B | -2 B | -1.94 B | -1.8 B | -1.79 B | -1.64 B | -1.55 B | -1.43 B | -1.38 B | -1.33 B | -1.23 B | -1.16 B | -1.38 B | -1.3 B | -1.22 B | -1.13 B | -1.13 B | -1.13 B | -1.13 B | -708 M | -708 M | -708 M | -708 M | -967 M | -967 M | -967 M | -967 M | -1.24 B | -1.24 B | -1.24 B | -1.24 B | -1.18 B | -1.18 B | -1.18 B | -1.18 B | -1.09 B | -1.09 B | -1.09 B | -1.09 B | -1.01 B | -1.01 B | -1.01 B | -1.01 B | -968 M | -968 M | -968 M | -968 M | -907 M | -907 M | -907 M | -907 M | -841 M | -841 M | -841 M | -841 M |
Total Assets |
3.08 B | 2.69 B | 2.76 B | 2.99 B | 2.93 B | 2.97 B | 2.89 B | 2.53 B | 2.42 B | 2.46 B | 2.52 B | 2.61 B | 2.41 B | 2.5 B | 2.25 B | 2.39 B | 2.39 B | 2.39 B | 2.39 B | 3.23 B | 3.23 B | 3.23 B | 3.23 B | 2.67 B | 2.67 B | 2.67 B | 2.67 B | 1.32 B | 1.32 B | 1.32 B | 1.32 B | 912 M | 912 M | 912 M | 912 M | 948 M | 948 M | 948 M | 948 M | 956 M | 956 M | 956 M | 956 M | 847 M | 847 M | 847 M | 847 M | 546 M | 546 M | 546 M | 546 M | 485 M | 485 M | 485 M | 485 M |
Cash and Cash Equivalents |
335 M | 294 M | 349 M | 399 M | 352 M | 425 M | 309 M | 276 M | 315 M | 522 M | 543 M | 869 M | 633 M | 565 M | 414 M | 398 M | 398 M | 398 M | 398 M | 683 M | 683 M | 683 M | 683 M | 279 M | 279 M | 279 M | 279 M | 130 M | 130 M | 130 M | 130 M | 84.7 M | 84.7 M | 84.7 M | 84.7 M | 129 M | 129 M | 129 M | 129 M | 143 M | 143 M | 143 M | 143 M | 160 M | 160 M | 160 M | 160 M | 124 M | 124 M | 124 M | 124 M | 65.5 M | 65.5 M | 65.5 M | 65.5 M |
Book Value |
662 M | 264 M | 297 M | 387 M | 315 M | 428 M | 487 M | 573 M | 594 M | 625 M | 710 M | 772 M | 531 M | 583 M | 681 M | 743 M | 743 M | 743 M | 743 M | 1.68 B | 1.68 B | 1.68 B | 1.68 B | 1.19 B | 1.19 B | 1.19 B | 1.19 B | 365 M | 365 M | 365 M | 365 M | 99.6 M | 99.6 M | 99.6 M | 99.6 M | 201 M | 201 M | 201 M | 201 M | 258 M | 258 M | 258 M | 258 M | 378 M | 378 M | 378 M | 378 M | 183 M | 183 M | 183 M | 183 M | 171 M | 171 M | 171 M | 171 M |
Total Shareholders Equity |
662 M | 264 M | 297 M | 387 M | 315 M | 428 M | 487 M | 573 M | 594 M | 625 M | 710 M | 772 M | 531 M | 583 M | 681 M | 743 M | 743 M | 743 M | 743 M | 1.47 B | 1.47 B | 1.47 B | 1.47 B | 1.05 B | 1.05 B | 1.05 B | 1.05 B | 281 M | 281 M | 281 M | 281 M | 99.6 M | 99.6 M | 99.6 M | 99.6 M | 201 M | 201 M | 201 M | 201 M | 258 M | 258 M | 258 M | 258 M | 378 M | 378 M | 378 M | 378 M | 183 M | 183 M | 183 M | 183 M | 171 M | 171 M | 171 M | 171 M |
All numbers in USD currency